To the Editor-In a recently published article, Hirsch et al. [1] reviewed HIV drug resistance assays used in clinical practice and described a "virtual phenotype" that correlates genotypic data on the plasma HIV-1 RNA of a candidate gene with a large database of paired phenotypes and genotypes. Although the authors cite other bioinformatics systems that generate a calculated fold change (FC), our comments are specific to the Virco Type HIV-1.
Hirsch et al. [1] state that virtual phenotype resistance interpretations are limited by a methodology that relies on matches that are based on preselected codons and not on the entire nucleotide sequence and that the "predictive power depends on the number of matched datasets available" [1, p. 274] , with high variation for newer drugs with smaller datasets. We would like to note that the matching system used to calculate the FC in their article is no longer the methodology used by the Virco assay. Since July 2006, Virco's bioinformatics engine has been used to calculate the FC for a given sample by the following method [2] .
First, linear regression modeling is performed periodically to analyze the relationship between genotype and phenotype in the Virco correlative database, which to date, has 153,000 samples with paired genotypic and phenotypic data. Significant mutations and mutation pairs that affect phenotypic susceptibility to each drug are identified, and their negative or positive impact on the FC is quantified by a resistance weight factor.
Second, all of the mutations in a sample genotype are compared on a drug-by-drug basis to the current list of resistance weight factors for the drug. An FC score is then generated by calculating the sum of the values for all resistance weight factors identified in the sample genotype.
This methodology is unlike the first generation of the virtual phenotype, which sought to identify matches to viruses with very similar mutational profiles. 
Reply to Bellosillo et al.
To the Editor-Bellosillo et al. [1] correctly note that our description of the procedures used to generate a virtual phenotype was incorrectly based on an older approach that is no longer in use. We appreciate their highlighting the linear regression models that form the basis of the current system. We do note that the overall size of the database of paired genotypes and phenotypes is still important, that the number of phenotypes for newer drugs will be fewer than that for older drugs (and, hence, the strength of the linear regression models will be correspondingly weaker), and that the number of samples with a given mutation in the database does have an effect on the precision of the estimated contribution to the drug susceptibility of that particular mutation [2] . 
